Immuno-Oncology's Biomarker Dilemma - How To Add Value In An Uncertain Development Landscape - a podcast by Drug Discovery World (DDW)

Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated.

For more information on Drug Discovery World, head to:

http://www.ddw-online.com

Further episodes of The Drug Discovery World Podcast

Further podcasts by Drug Discovery World (DDW)

Website of Drug Discovery World (DDW)